NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer Clinical Trial

Official title:
Hepatic Artery Transfusion of NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer: a Prospective, Multicenter Clinical Trial

Status Recruiting

Clinical Trial Summary

Evaluate the clinical safety and feasibility of NKG2D CAR-T administrated by hepatic artery transfusion for patients with previously treated liver metastatic colorectal cancer.

Clinical Trial Description

Evaluate the clinical safety and feasibility of NKG2D CAR-T administrated by hepatic artery transfusion for patients with previously treated liver metastatic colorectal cancer. Evaluate the maximum tolerated dose (MTD), dose limiting toxicities (DLT), and toxicity spectrum of NKG2D CAR-T treatment administrated by hepatic artery transfusion. Secondary Objectives: Evaluate the efficacy of NKG2D CAR-T administrated by hepatic artery transfusion for patients with previously treated liver metastatic colorectal cancer, including PSF, DCR, SD >= 8 weeks, ORR, OS, and DOR. ;

Study Design

Related Conditions & MeSH terms

Colorectal Neoplasms
Refractory Metastatic Colorectal Cancer

Clinical Trial Details

NCT number	NCT05248048
Study type	Interventional
Source	The Third Affiliated Hospital of Guangzhou Medical University
Contact	Xuehu Xu, MD
Phone	13609020099
Email	maxtiger@126.com
Status	Recruiting
Phase	Early Phase 1
Start date	September 13, 2021
Completion date	October 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04527068` - QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer	Phase 2
Completed	`NCT04737187` - Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients	Phase 3
Active, not recruiting	`NCT05205330` - A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients	Phase 1/Phase 2
Active, not recruiting	`NCT05733611` - RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Phase 2
Recruiting	`NCT05991102` - Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer	N/A
Recruiting	`NCT05213195` - NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer	Phase 1
Completed	`NCT02860546` - A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC	Phase 2
Not yet recruiting	`NCT06343116` - Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer	Phase 3